IMAGE IN CARDIOLOGY

DOI: 10.4244/EIJY15M02_01

Implantation of a novolimus-eluting bioresorbable scaffold with a strut thickness of 100 µm showing evidence of self-correction

Jens Wiebe1, MD; Timm Bauer1, MD; Oliver Dörr1, MD; Helge Möllmann2, MD; Christian W. Hamm1,2, MD; Holger M. Nef1*, MD

Practical concerns regarding poly-L-lactic acid (PLLA)-based bioresorbable scaffolds (BRS) are mostly related to the strut thickness of 150 µm. Implantation may cause more vessel injury as well as non-laminar flow and activation of platelet function. Furthermore, constraints of deliverability preclude BRS use in the presence of tortuosity or severe calcification. The PLLA-based novolimus-eluting DESolve® 100 scaffold (Elixir Medical Corporation, Sunnyvale, CA, USA) has a strut thickness of 100 µm. Complete degradation is achieved within two years. Furthermore, it has wider expansion ranges than other BRS and self-correction properties corresponding to nominal diameters, which can resolve minor malapposition.

In a mid-RCX stenosis, predilatation was performed with a non-compliant and a scoring balloon. Thereafter, a 2.5/28 mm BRS was implanted. Optical coherence tomography (OCT) revealed malapposition with a maximum vessel-wall distance of 0.33 mm and further edge dissection. Thus, a second 2.5/14 mm BRS was implanted distally. Another OCT run revealed a reduction of malapposition of the first BRS within 15 minutes: the vessel-wall distance decreased from 0.33 mm to 0.25 mm, and the minimal scaffold area increased from 3.94 mm2 to 4.28 mm2 (Figure 1). Nevertheless, malapposition was still present and post-dilatation was implemented with a non-compliant balloon. Final OCT confirmed a satisfactory result. The Online Appendix, Online Figure 1, Online Figure 2 and Moving image 1-Moving image 6 can be found online. The in vitro scaffold cross-sectional area under nominal pressure for the 2.5 mm DESolve 100 is 4.91 mm2, thus further self-correction is presumable. Self-correction appears reasonable especially in the presence of thrombi. Additional investigations will certainly be required for a conclusive proof-of-concept.

Figure 1. Evidence of malapposition and self-correction. Directly after implantation, malapposition was detected by OCT with a maximum vessel-wall distance of 0.33 mm. After 15 minutes, malapposition was decreased and the maximum vessel-wall distance was 0.25 mm.

Acknowledgements

We would like to acknowledge the assistance of Elizabeth Martinson, PhD, for helpful editing and advice in the preparation of the manuscript.

Conflict of interest statement

H. Nef has received speaker’s honoraria from Elixir Medical. The other authors have no conflicts of interest to declare.

Online data supplement

Online Appendix. Sequence of baseline and procedural imaging.

Online Figure 1. Scaffold implantation using the marker-over-marker technique.

Online Figure 2. Post-dilatation with a non-compliant balloon.

Moving image 1. Baseline angiography.

Moving image 2. Baseline OCT.

Moving image 3. Predilatation with a non-compliant balloon.

Moving image 4. Predilatation with a scoring balloon.

Moving image 5. Final angiography.

Moving image 6. Final OCT.

Online Appendix. Sequence of baseline and procedural imaging

Baseline angiography revealed a stenosis of the mid-RCX and another of the ostial RCX (Moving image 1). Additional optical coherence tomography imaging confirmed the angiographic findings (Moving image 2).

Predilatation was performed with a non-compliant balloon (2.5/20 mm) (Moving image 3) and with a scoring balloon (2.5/10 mm) at the site of lesion (Moving image 4). A 2.5/28 mm DESolve 100 scaffold was implanted. Due to distal edge dissection a further 2.5/14 mm DESolve 100 was implanted distally. The ClearStent technology demonstrated that implantation was performed in a marker-over-marker technique (Online Figure 1). Post-dilatation was performed with a non-compliant balloon (Online Figure 2) and final angiography showed TIMI 3 flow and a reasonable result (Moving image 5), which was further confirmed by OCT (Moving image 6).

Online Figure 1. Scaffold implantation using the marker-over-marker technique.

Online Figure 2. Post-dilatation with a non-compliant balloon.

Volume 11 Number 2
Jun 19, 2015
Volume 11 Number 2
View full issue


Key metrics

Suggested by Cory

Debate

10.4244/EIJ-E-23-00015 Jun 19, 2023
Bioresorbable coronary scaffolds are ready for a comeback: pros and cons
Stone GW et al
free

10.4244/EIJV11I12A259 Mar 18, 2016
Oversized post-dilatation of current bioresorbable vascular scaffolds: kill or cure?
von Birgelen C and Basalus M
free

EXPERT REVIEW

10.4244/EIJ-D-17-00499 Aug 25, 2017
State of the art: the inception, advent and future of fully bioresorbable scaffolds
Katagiri Y et al
free

10.4244/EIJV16I2A16 Jun 12, 2020
Bioresorbable scaffolds: did we jump the gun?
Waksman R and Forrestal B
free

10.4244/EIJV15I1A5 May 20, 2019
Should we stop using bioresorbable scaffolds in coronary revascularisation?
Mangieri A and Colombo A
free

10.4244/EIJV9I7A128 Nov 29, 2013
Kissing vanishing stents: are we trading ephemeral benefit for permanent damage?
Di Mario C et al
free

10.4244/EIJV13I13A242 Jan 19, 2018
Polymeric bioresorbable coronary scaffolds: the hype is over, but the dream lives on
Pyxaras S and Wijns W
free

10.4244/EIJV11SVA40 May 19, 2015
Bioresorbable scaffolds on the bench
Ormiston J et al
free
Trending articles
152.9

Clinical research

10.4244/EIJ-D-20-01125 Oct 20, 2021
An upfront combined strategy for endovascular haemostasis in transfemoral transcatheter aortic valve implantation
Costa G et al
free
47.8

NEW INNOVATION

10.4244/EIJ-D-15-00467 Feb 20, 2018
Design and principle of operation of the HeartMate PHP (percutaneous heart pump)
Van Mieghem NM et al
free
39.1

Clinical research

10.4244/EIJ-D-22-00558 Feb 6, 2023
Permanent pacemaker implantation and left bundle branch block with self-expanding valves – a SCOPE 2 subanalysis
Pellegrini C et al
free
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 7.6
2023 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2024)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2024 Europa Group - All rights reserved